title: Reactive murine lymph nodes uniquely permit parenchymal access for T cells that enter via the afferent lymphatics.
abstract: Whereas naïve T cells access the lymph nodes predominantly via the high endothelial venules, their effector counterparts can also enter via the afferent lymphatics. It is unclear if such cells are confined to the lymphatic spaces during their transit through the lymph node or whether they can access the lymphocyte- and dendritic cell-rich parenchyma with its potentially stimulatory environment. We used a flank HSV inoculation model that featured neuronal-mediated movement of virus to distinct areas of skin to study the lymphatic-mediated transit of activated T cells between different skin-draining lymph nodes. These experiments showed that activated T cells released from the brachial lymph node, draining the primary site of inoculation, entered the downstream axillary lymph node. These activated T cells accessed the subcapsular areas of the axillary lymph node via lymphatic vessels exiting the upstream brachial node regardless of whether the former drained skin that was associated with active infection. However, T cells remained within the sinusoidal network of the axillary lymph node unless it was directly associated with peripheral infection. Thus, activated T cells that enter a given lymph node using the afferent lymphatics do not have automatic access to the parenchyma unless it is a reactive node involved with peripheral inflammation or infection.
authors.affiliation: Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Victoria 3010, Australia.
authors.forename: Liv
authors.initials: L
authors.lastname: Eidsmo
authors.forename: Angus T
authors.initials: AT
authors.lastname: Stock
authors.forename: William R
authors.initials: WR
authors.lastname: Heath
authors.forename: Sammy
authors.initials: S
authors.lastname: Bedoui
authors.forename: Francis R
authors.initials: FR
authors.lastname: Carbone
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D002634:Chemotaxis, Leukocyte; D004195:Disease Models, Animal; D000068876:Fingolimod Hydrochloride; D019672:Genes, T-Cell Receptor; D006561:Herpes Simplex / Q000235:genetics / Q000276:immunology* / Q000821:virology; D018259:Herpesvirus 1, Human / Q000276:immunology / Q000472:pathogenicity; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008198:Lymph Nodes / Q000276:immunology* / Q000821:virology; D042601:Lymphatic Vessels / Q000276:immunology* / Q000821:virology; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011409:Propylene Glycols / Q000494:pharmacology; D012867:Skin / Q000276:immunology* / Q000821:virology; D013110:Sphingosine / Q000031:analogs & derivatives / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation / Q000821:virology; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine